ImmuCell Corporation
NASDAQ:ICCC · NASDAQ Capital Market
+$0.19 today
Vol 0.03M · Avg 0.03M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-3.8%
avg -4.4%
ROIC
4.1%
avg -1.6%
ROA
-2.4%
avg -2.7%
Analysis
ROIC is currently the strongest return metric at 4.1% versus its period average of -1.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Bobbi Jo Brockmann | Senior Vice President of Sales & Marketing | $425,816.00 | — | 49 | $100,000.00 | 1.11% |
Timothy C. Fiori | Chief Financial Officer, Secretary, Treasurer & Director | $337,280.00 | — | 47 | $120,000.00 | 1.33% |
F. Olivier Te Boekhorst | President, Chief Executive Officer & Director | $172,665.00 | — | — | $0.00 | <0.01% |
Paul F. Olivier Te Boekhorst | President, Chief Executive Officer & Director | $172,665.00 | — | 54 | $0.00 | <0.01% |
A. Gustavo Scaffa | Senior Director of Quality | — | — | — | — | — |
Elizabeth S. Toothaker | Director of Finance & Administration and Controller | — | — | — | $1,000.00 | 0.01% |
John W. Zinckgraf | Director of Product Development | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
7
$95,671.11
Sells
0
$0.00
Net Sentiment
+$95,671.11
Net buying
Most Active
te Boekhorst Paul Francis Olivier
5 transactions
Analysis
Insiders reported 7 buys worth $95,671.11 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $95,671.11. te Boekhorst Paul Francis Olivier was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +133.1% | N/A1 analysts |
| Revenue | N/A | N/A | +23.8% | +5.4% (12yr)1 analysts |
| Net Income | N/A | N/A | +138.4% | N/A1 analysts |
| EBIT | N/A | N/A | +105.4% | N/A1 analysts |
Analysis
Recent growth has been strongest in Net Income at +138.4% over three years. Forward estimates point to Revenue at +5.4% (12yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Century Therapeutics, Inc.
NASDAQ:IPSC
$196.58M
Equillium, Inc.
NASDAQ:EQ
$107.81M
Fortress Biotech, Inc.
NASDAQ:FBIO
$100.49M
OS Therapies Incorporated
AMEX:OSTX
$81.06M
Cue Biopharma, Inc.
NASDAQ:CUE
$70.99M
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
$69.75M
Outlook Therapeutics, Inc.
NASDAQ:OTLK
$63.36M
Coeptis Therapeutics, Inc.
NASDAQ:COEP
$55.98M
Genenta Science S.p.A.
GNTA
$32.55M
Senti Biosciences, Inc.
SNTI
$24.58M
Who manages ICCC?
ImmuCell Corporation (ICCC) lists 7 active executives. The top listed executive is Bobbi Jo Brockmann, Senior Vice President of Sales & Marketing.
Are ICCC insiders buying or selling?
Recent insider activity shows net buying of $7.24M.
Explore More
Continue the stock analysis
Jump to another research area for this company.